Increase your understanding of how the Oncotype DX GPS assay refines patient risk levels for more informed treatment decisions.Select an NCCN risk group in step 1 and then add a GPS score in step 2 to see how the combination gives you a more informed risk across multiple clinical endpoints and individualized risk factors.
STEP 1: SELECT AN NCCN RISK GROUP ?
STEP 2: SELECT A GPS RESULT ? The Average GPS score for the NCCN Low risk group is 12
Show adjustable scale from 0 to 100, intervals of 5.
GPS + NCCN®: Very Low Risk
The combination of NCCN® and GPS has resulted in a Downgraded Risk
Text and 3 balloons here
Clinical Interpretation - Clinical Endpoints - Individualized Risk
The combination of GPS and
clinical features predicts that
this patient's risk is consistent
with NCCN Very Low Risk
In a clinical validation study
including patients with NCCN
Very Low, Low, and
intermediate Risk, no patient
with a GPS result <20 had="" metastasis="" or="" died="" from="" prostate="" cancer="" within="" 10="" years.="">20>